Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry

Two decades after the introduction of tyrosine kinase inhibitors (TKI), a sizeable portion of patients with chronic myeloid leukemia (CML) in chronic phase (CP) still undergo allogeneic stem cell transplantation (allo-HSCT). We investigated the indications for allo-HSCT, clinical outcome, management...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 2019-11, Vol.54 (11), p.1764-1774
Hauptverfasser:	Lübking, Anna, Dreimane, Arta, Sandin, Fredrik, Isaksson, Cecilia, Märkevärn, Berit, Brune, Mats, Ljungman, Per, Lenhoff, Stig, Stenke, Leif, Höglund, Martin, Richter, Johan, Olsson-Strömberg, Ulla
Format:	Artikel
Sprache:	eng
Schlagworte:	692/699/1541/1990/283/1896 692/700/565/1436/2185 692/700/565/2319 Adolescent Adult Aged Allografts Blast crisis Cell Biology Chronic myeloid leukemia Diagnosis Disease-Free Survival Female Hematology Hematopoietic Stem Cell Transplantation Humans Internal Medicine Kinases Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy Male Medicine Medicine & Public Health Middle Aged Mortality Myeloid leukemia Patient outcomes Patients Protein Kinase Inhibitors Protein-tyrosine kinase Public Health Registries Risk analysis Risk factors Stem cell transplantation Stem Cells Survival Survival Rate Sweden - epidemiology Time Factors Transplantation Transplants & implants Tyrosine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!